SCHEMBL7940868

SCHEMBL7940868

Cc1cccc(-c2sccc2C)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 8/20 0.58
CYP3A4 P08684 4/20 0.53
CYP2C19 P33261 4/20 0.53
CYP2B6 P20813 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2E1 P05181 1/20 0.53
PGR P06401 2/20 0.44
ACHE P22303 1/20 0.42
MEN1 O00255 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
CYP1A2 P05177 2/20 0.41
RAB9A P51151 2/20 0.39
PRKDC P78527 1/20 0.38
CNR1 P21554 2/20 0.38
CNR2 P34972 2/20 0.38
NPC1 O15118 1/20 0.38
HPGD P15428 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL694184 0.81 CYP2A6 (0.53) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL28002826 0.81 ALDH1A1 (0.42) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL13617123 0.81 ALDH1A1 (0.45) CYP2A6ACHEMEN1ALDH1A1KMT2A
SCHEMBL13592024 0.81 CYP2A6 (0.50) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL10406976 0.81 CYP2A6 (0.50) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL1821918 0.79 CYP2A6 (0.60) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL10406611 0.78 CYP2A6 (0.47) CYP2A6CYP3A4CYP2C19CYP2B6CYP2D6
SCHEMBL28528852 0.78 ATP4A (0.38) CYP2A6ACHEMEN1ALDH1A1KMT2A
SCHEMBL28358715 0.78 CNR1 (0.40) CYP2A6ACHEMEN1ALDH1A1KMT2A
SCHEMBL1339482 0.77 AKR1C2 (0.50) MEN1ALDH1A1KMT2AKDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063099-B2 Trans-3-aza-bicyclo[3.1.0]hexane derivatives ACTELION PHARMACEUTICALS LTD. (CH) 2011-11-22 US disclosed
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-05-05 US disclosed
EP-2185512-B1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2010-12-29 EP disclosed
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD. (CH) 2010-08-12 US disclosed
WO-2010004507-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS ACTELION PHARMACEUTICALS LTD (CH) 2010-01-14 WO disclosed
WO-2009016560-A2 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2009-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105491-A1 THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, OXTR CYP2A6 1392/4885CYP3A4 976/4885CYP2C19 1253/4885
US-20100204285-A1 TRANS-3-AZA-BICYCLO[3.1.0]HEXANE DERIVATIVES HCRTR1, HCRTR2, CNR1 CYP2A6 512/4885CYP3A4 500/4885CYP2C19 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.